CTI BioPharma (CTIC) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. DOX
3. BKNG
4. DUOL
5. SWKS
6. AMGN
7. ANET
8. XYZ
9. CVS
10. FISV

Go back to CTI BioPharma (CTIC) Tops Q1 EPS by 2c

CTI BioPharma Reports First Quarter 2018 Financial Results

May 3, 2018 4:01 PM EDT

SEATTLE, May 3, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today reported financial results for the first quarter ended March 31, 2018.

In March 2018, results from the Phase 3 PERSIST-2 clinical trial of pacritinib were published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy, which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis and thrombocytopenia (defined as platelet counts 100 x 109/L).

Upcoming Milestones

In the second quarter... More